secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0000728387-26-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics reports FY2025 net loss $103M; lead program shows durable responses; cash ~$309M post-offering
--------------------------------------------------------------------------------

- Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).
- Cash $145M at Dec 31, 2025; Feb 2026 equity offering net proceeds ~$164M; runway into late 2027.
- VMT-α-NET: 76% progression-free at ~13 weeks additional follow-up; 39% objective response rate in Cohort 2.
- Cohort 3 cleared for more patients; all Cohort 2 expected to have ≥48 weeks follow-up by mid-2026.
- $10M non-cash impairment for deprioritized preclinical asset; three clinical programs continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/0000728387-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/catx-20260316.htm
  HTML page:      https://secwatch.observer/filing/0000728387-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer